Vectibix (panitumumab) / Dr. Reddy’s, Amgen, Takeda  >>  Phase 3
Welcome,         Profile    Billing    Logout  

32 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vectibix (panitumumab) / Amgen
NCT00115765: PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

Completed
3
1053
NA
Oxaliplatin Based Chemotherapy, FOLFOX 4, FOLFOX 5, Modified FOLFOX 6, FOLFOX 7, Oxaliplatin, Panitumumab, pmab, Vectibix, Irinotecan Based Chemotherapy, FOLFIRI, Douillard, Bevacizumab, Avastin
Amgen
Colorectal Cancer
05/07
05/09
NCT00113763: Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark
Apr 2013 - Apr 2013: 
Completed
3
463
NA
Best supportive care, Panitumumab, ABX-EGF
Amgen
Colorectal Cancer, Metastases
10/08
06/09
NCT00339183: Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Checkmark ESMO WCGI 2014
Jun 2014 - Jun 2014: ESMO WCGI 2014
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P3 data
More
Completed
3
1186
NA
Panitumumab, Vectibix®, FOLFIRI
Amgen
Metastatic Colorectal Cancer
04/09
11/10
PRIME, NCT00364013: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Checkmark PRIME trial
May 2016 - May 2016: PRIME trial
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark In pts with previously untreated mCRC
More
Completed
3
1183
NA
Panitumumab, Vectibix®, FOLFOX regimen
Amgen
Metastatic Colorectal Cancer
08/09
03/13
SPECTRUM, NCT00460265: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Checkmark In combination with Cisplatin & fluorouracil in pts with recurrent or mets SCCHN
Jun 2013 - Jun 2013: In combination with Cisplatin & fluorouracil in pts with recurrent or mets SCCHN
Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Completed
3
658
US, Canada, Europe, RoW
ARM 2, ARM 1
Amgen
Recurrent and/or Metastatic Head and Neck Cancer
05/10
05/12
NCT01142414 / 2008-006180-36: Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence

Checkmark P3 data
Jun 2011 - Jun 2011: P3 data
Withdrawn
3
0
RoW
panitumumab, cisplatin, fluorouracil, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
 
 
2006-003786-13: A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed
3
650
Europe, RoW
Panitumumab, AMG954, Intravenous infusion, Vectibix
Amgen Inc, Amgen Inc., AMGEN S.P.A.
Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
 
 
REAL3, NCT00824785 / 2007-005976-15: Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark
Apr 2013 - Apr 2013: 
Checkmark Biomarker data
More
Terminated
3
574
Europe
epirubicin, oxaliplatin, capecitabine (EOX), EOX + panitumumab
Royal Marsden NHS Foundation Trust
Oesophago-gastric Cancer
02/13
02/13
ASPECCT, NCT01001377 / 2009-010715-32: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO-GI 2016
More
Completed
3
1010
Europe, Canada, US, RoW
Cetuximab, Erbitux, Panitumumab, Vectibix
Amgen
Metastatic Colorectal Cancer
02/13
03/17
NCT01412957 / 2010-022951-49: Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO-GI 2016
More
Completed
3
377
Canada, Europe, RoW
Best Supportive Care (BSC), Panitumumab, Vectibix
Amgen
Metastatic Colorectal Cancer
06/14
11/16
POWER, NCT01627379 / 2010-020606-15: Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

Terminated
3
300
Europe
Cisplatin, 5-FU, Panitumumab
AIO-Studien-gGmbH, Amgen, Assign Data Management and Biostatistics GmbH, Assign Clinical Research GmbH
Esophageal Squamous Cell Cancer
05/15
05/17
NCT00820248: Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
3
320
Canada
panitumumab, cisplatin, 3-dimensional conformal radiation therapy, accelerated radiation therapy, intensity-modulated radiation therapy
NCIC Clinical Trials Group
Head and Neck Cancer
05/15
02/17
2005-004676-20: A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer

 
3
120
Europe
Panitumumab, AMG954, Panitumumab, Panitumumab
Amgen Limited, Amgen Inc., Amgen Inc, AMGEN S.P.A.
Patients with Previously Treated Metastatic Colorectal Cancer
 
09/10
2006-000170-70: A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin Alone in Patients with Previously Untreated Metastatic Colorectal Cancer

 
3
130
Europe
Panitumumab, AMG954,
Amgen Inc, AMGEN S.P.A.
Patients with Previously Untreated Metastatic Colorectal Cancer
 
01/13
GETUG-AFU19, NCT02818725 / 2009-011882-10: I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

Completed
3
133
Europe
Chemotherapy, Intensified-Methotrexate Vinblastine Doxorubicin Cisplatin, I-MVAC, Panitumumab
UNICANCER
Infiltrating Urothelial Carcinoma, KRAS Gene Mutation
09/16
09/17
2016-004394-40: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.

Ongoing
3
432
Europe
Panitumumab, Fluorouracile, Oxaliplatino, Calcio Levofolinato, Irinotecan, [Panitumumab], [Fluorouracile], [Oxaliplatino], [Calcio Levofolinato], [Irinotecan], Solution for infusion, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, CALCIO LEVOFOLINATO TEVA - 25 MG POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, IRINOTECAN CSC - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML
Fondazione GONO, Amgen, G.O.N.O.
Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04]
 
 
NCT01311453: A Trial to Evaluate the Benefit and Efficacy of Liver Transplantation as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma

Recruiting
3
60
Europe
Transplantation, Chemotherapy
Oslo University Hospital
Overall Survival, Progression Free Survival
01/19
09/19
NCT04342676: Lymph Node Ratio and Kras Mutation in R Colon Cancer

Completed
3
433
RoW
k ras, Panitumumab, vectibex
Mansoura University
Colon Cancer Stage III
08/19
08/19
NCT03300609: 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Terminated
3
4
US
Panitumumab, 339177-26-3, ABX-EGF, ABX-EGF Monoclonal Antibody, Clone E7.6.3, MoAb ABX-EGF, Monoclonal Antibody ABX-EGF, Vectibix, Oxaliplatin, 1-OHP, 266046, 61825-94-3, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, oxalato (1R,2R-cyclohexanediamine)platinum(II), oxalato (trans-l-1,2-diaminocyclohexane)platinum(II), Oxalatoplatin, Oxalatoplatinum, RP-54780, SR-96669, trans-l DACH oxalatoplatinum, trans-l diaminocyclohexane oxalatoplatinum, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, 5-Formyl-5,6,7,8-tetrahydrofolic Acid, 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Fusilev, Lederfolat, Lederfolin, Leucosar, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Fluorouracil, 19893, 2,4-Dioxo-5-fluoropyrimidine, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 51-21-8, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Capecitabine, 154361-50-9, 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine, 712807, Ro 09-1978/000, Xeloda, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis
University of Southern California, National Cancer Institute (NCI), Amgen
Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
10/19
10/19
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
PARADIGM, NCT02394795: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Checkmark PARADIGM study
May 2016 - May 2016: PARADIGM study
Completed
3
823
Japan
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Takeda
Colorectal Cancer
01/22
01/22
NCT00389870 / 2005-003492-20: Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Panitumumab, irinotecan & ciclosporin in adv CRC pts
Aug 2013 - Aug 2013: Panitumumab, irinotecan & ciclosporin in adv CRC pts
Checkmark In combination with irinotecan in pts with KRAS wild-type, fluorouracil-resistant adv CRC
More
Completed
3
1198
Europe
panitumumab, cyclosporine, irinotecan hydrochloride
University of Leeds
Colorectal Cancer
 
 
TRIPLETE, NCT03231722: First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Completed
3
435
Europe
Panitumumab, Irinotecan, Oxaliplatin, l-leucovorin, 5-fluorouracil
Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
06/22
06/22
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Recruiting
3
564
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
08/22
07/25
CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting
3
355
RoW
Cetuximab, panitumumab
City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
12/26
12/27
PARADIGM biomarker, NCT02394834: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active, not recruiting
3
757
Japan
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Takeda
Colorectal Cancer
03/25
03/25
CR-SEQUENCE, NCT03635021 / 2018-000347-60: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Active, not recruiting
3
419
Europe
FOLFOX regimen, Panitumumab, Bevacizumab, FOLFIRI regimen
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen
Colorectal Cancer
06/25
06/25
CodeBreaK 301, NCT06252649: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Not yet recruiting
3
450
NA
FOLFIRI Regimen, Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Bevacizumab-awwb, MVASI
Amgen
Metastatic Colorectal Cancer
05/27
12/30
CodeBreak 300, NCT05198934 / 2021-004008-16: Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Jul 2023 - Dec 2023: Data readout from CodeBreak 300 trial for colorectal cancer
Active, not recruiting
3
160
Europe, Japan, US, RoW
Sotorasib, AMG 510, Lumakras, Lumykras, Panitumumab, Vectibix, Trifluridine and Tipiracil, Lonsurf, Regorafenib, Stivarga
Amgen
Colorectal Cancer (CRC)
03/25
03/25
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting
3
348
Europe
Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI
Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms
09/25
09/27
NCT05863195: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting
3
408
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Floxuridine, 2'-Deoxy-5-fluorouridine, 5-Fluoro-2'-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR-138720, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Implantation, Intrahepatic Infusion Procedure, HAI, Hepatic Arterial Infusion, Hepatic Artery Infusion, IHI, Intrahepatic Infusion, Irinotecan, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
06/29
06/34
FOxTROT, NCT00647530 / 2007-001987-55: Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery

Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Unknown status
2/3
1053
Europe
panitumumab, capecitabine, fluorouracil, oxaliplatin
University of Birmingham
Colorectal Cancer
12/16
12/19

Download Options